List of Excipients in Branded Drug COGENTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oak Pharmaceuticals Inc (Subsidiary of Akorn Inc)	COGENTIN	benztropine mesylate	76478-611	SODIUM CHLORIDE
Oak Pharmaceuticals Inc (Subsidiary of Akorn Inc)	COGENTIN	benztropine mesylate	76478-611	WATER

Cogentin Excipient Strategy and Commercial Opportunities for Benztropine Mesylate

Last updated: August 12, 2026

Cogentin is the branded formulation of benztropine mesylate, an anticholinergic used for parkinsonism and drug-induced extrapyramidal disorders. Its commercial opportunity is primarily generic and formulation-driven. The strongest opportunities are in differentiated oral products, preservative-free injectable presentation, institutional packaging, and excipient systems that improve swallowing, dose flexibility, and supply reliability.

Benztropine is an established, low-cost active pharmaceutical ingredient with limited apparent patent-based exclusivity. Commercial success is therefore more likely to depend on regulatory efficiency, manufacturing cost, shortage prevention, and product usability than on premium pricing for the molecule itself.

What products and dosage forms does Cogentin include?

Cogentin has historically been supplied as oral tablets and an injectable solution containing benztropine mesylate. U.S. labeling identifies tablet strengths of 0.5 mg, 1 mg, and 2 mg, while the injection is supplied at 1 mg/mL.[1]

Product characteristic	Cogentin / benztropine product
Active ingredient	Benztropine mesylate
Pharmacologic class	Centrally acting anticholinergic
Main uses	Drug-induced extrapyramidal disorders; parkinsonism
Oral strengths	0.5 mg, 1 mg, 2 mg
Injectable strength	1 mg/mL
Primary markets	Psychiatry, neurology, hospitals, long-term care
Regulatory pathway for equivalent generic	Abbreviated New Drug Application, or ANDA
Likely differentiated-formulation pathway	505(b)(2) NDA
Biosimilar relevance	None; benztropine is a small molecule

The injectable product has a narrower commercial base than the tablets because it is used mainly in acute-care and institutional settings. Oral tablets are the larger platform for generic competition and line extensions.

What excipients are used in Cogentin tablets and injection?

The exact inactive-ingredient profile depends on the manufacturer and product presentation. Public labeling for benztropine products identifies conventional solid-dose excipients such as lactose, starch, talc, and magnesium stearate in tablet formulations, while injectable products use an aqueous vehicle and tonicity-adjusting excipients.[1,2]

Tablet excipient profile

A conventional benztropine tablet may use:

• Lactose as a diluent
• Starch as a filler and disintegrant
• Magnesium stearate as a lubricant
• Talc as a glidant or processing aid
• Tablet coating components, where applicable
• Colorants for strength differentiation

These excipients are familiar to generic manufacturers and generally support a low-cost immediate-release product. The main technical risks are content uniformity at the 0.5 mg strength, tablet robustness, dissolution consistency, and patient acceptability in older adults.

The 0.5 mg presentation is particularly important for titration. A formulation that produces reliable low-dose content uniformity can support a differentiated regulatory and commercial position even without a new active ingredient.

Injectable excipient profile

The injection is an aqueous benztropine mesylate solution. Its formulation depends on pH control, tonicity, chemical stability, particulate control, container compatibility, and sterility assurance.[1,2]

Potential excipient categories include:

• Water for injection
• Sodium chloride or another tonicity agent
• pH-adjusting agents
• Antimicrobial preservatives, if the presentation is multidose
• Chelating or stabilizing agents, where justified by stability data

A preservative-free, single-dose presentation can have a stronger hospital value proposition than a conventional multidose vial. It may reduce preservative exposure and simplify medication-use protocols, although the commercial case depends on container, fill-finish, and packaging costs.

What excipient strategies could differentiate a benztropine generic?

The most commercially credible excipient strategies are those that solve a defined administration or manufacturing problem.

Low-dose content uniformity

Benztropine tablets contain a small quantity of active ingredient. A robust formulation can use geometric dilution, carrier-based premixing, engineered granulation, or improved powder-flow excipients to reduce potency variation.

Potential formulation tools include:

• Co-processed microcrystalline cellulose and mannitol
• Spray-dried lactose systems
• Low-moisture starch or directly compressible starch
• Silicified microcrystalline cellulose
• Colloidal silicon dioxide for flow control
• Granulation systems that limit segregation

The commercial benefit is strongest when the formulation improves process capability without materially increasing tablet size or cost.

Swallowing and geriatric usability

Benztropine is commonly used in older patients with parkinsonism and in patients receiving multiple psychiatric medicines. A smaller, smoother, or orally disintegrating tablet could improve administration for patients with dysphagia.

Potential products include:

• Orally disintegrating tablets
• Chewable tablets
• Mini-tablets
• Scored tablets with improved dose splitting
• Taste-masked oral granules
• Ready-to-use oral solution

An orally disintegrating benztropine product would likely require a 505(b)(2) strategy unless the sponsor can establish that the dosage form and product characteristics fit an ANDA pathway. The sponsor would need to address taste, dose uniformity, moisture sensitivity, packaging, and bioequivalence.

Oral solution

An oral solution could offer dose flexibility, especially during titration or in patients unable to swallow tablets. The formulation would require attention to:

• Benztropine solubility across the target pH range
• Chemical stability in aqueous media
• Preservative efficacy
• Palatability
• Sorbitol or sugar load
• Measuring-device accuracy
• Container closure compatibility

A solution may create a distinct product rather than simply replacing tablets. Its commercial value is greatest in long-term care, specialty pharmacy, and patients requiring individualized doses.

Modified-release formulation

Modified release is technically possible but commercially less attractive. Benztropine is generally dosed in small amounts, and its use often requires clinical titration based on adverse effects and symptom control. A prolonged-release product would require evidence that smoother exposure improves treatment outcomes or tolerability.

Possible approaches include:

• Hydrophilic matrix tablets
• Multiparticulate capsules
• Ion-exchange resin complexes
• Polymer-coated pellets
• Osmotic delivery systems

The development burden would be higher than for an immediate-release generic. The product would also compete against low-cost tablets, limiting the price premium available to recover development costs.

What patent and exclusivity protections cover Cogentin?

Cogentin is an old small-molecule product, and the principal commercial barrier is generic competition rather than active branded patent exclusivity. The original product’s regulatory and patent protections date from an earlier era, while current benztropine products are generally marketed through generic pathways.

Protection category	Commercial assessment
Active-ingredient composition patents	Likely expired or commercially inactive
Original immediate-release formulation patents	Likely expired
New formulation patents	Potentially available for newly developed products
Method-of-use patents	Possible for narrowly defined uses, but not a clear basis for current Cogentin exclusivity
FDA small-molecule exclusivity	No apparent current branded exclusivity for established benztropine products
Biosimilar exclusivity	Not applicable
Orange Book strategy	Relevant to newly approved NDA formulations, not ordinary ANDA products

An innovator could pursue patents on a new dosage form, excipient system, taste-masking technology, container closure, or manufacturing process. Such patents would protect the differentiated product, not the established benztropine molecule itself.

What is the Orange Book status of Cogentin and benztropine?

The FDA Orange Book is the relevant source for listed U.S. approved drug products, therapeutic equivalence codes, and patent or exclusivity information for applicable NDA products.[3] Benztropine generic tablets and injection products are generally associated with the established generic market rather than an active period of branded exclusivity.

The practical implications are:

1. An ANDA sponsor can target existing tablet or injection presentations if it meets pharmaceutical equivalence and bioequivalence requirements.
2. A new dosage form may require a 505(b)(2) application.
3. Paragraph IV risk is more relevant to any future NDA formulation with listed patents than to the old immediate-release product.
4. A generic sponsor should verify current Orange Book listings before filing because product availability, discontinued status, and reference-product designation can change.

When does Cogentin lose exclusivity and when can generics launch?

For the established benztropine market, exclusivity loss occurred long ago. Generic entry is already commercially established. There is no meaningful single future “Cogentin patent cliff” comparable to the loss of exclusivity for a recent branded medicine.

Generic launch scenarios

Scenario	Regulatory route	Commercial outlook
Standard 0.5 mg, 1 mg, or 2 mg tablet	ANDA	Lowest development risk; price competition is intense
Equivalent 1 mg/mL injection	ANDA	Institutional opportunity; supply reliability matters
Orally disintegrating tablet	Likely 505(b)(2) or product-specific pathway	Higher differentiation and development cost
Oral solution	Likely 505(b)(2)	Useful for titration and dysphagia
Preservative-free injection	ANDA or 505(b)(2), depending on reference and formulation	Potential hospital and safety advantage
Extended-release product	505(b)(2)	Highest clinical and regulatory risk
Combination product	New drug application pathway	Limited rationale unless a clear treatment benefit exists

What Paragraph IV challenges and litigation affect benztropine?

Benztropine is not known as a current high-value Paragraph IV litigation market. Its established generic status reduces the incentive for expensive patent challenges. The relevant litigation risk would arise from a new formulation patent, manufacturing patent, or use patent asserted against a later entrant.

A sponsor launching a differentiated benztropine product should assess:

• Orange Book-listed patents for the reference NDA
• Patent listings covering dosage-form architecture
• Formulation patents covering taste masking or release control
• Use patents covering specific extrapyramidal-disorder populations
• Regulatory exclusivity associated with a new NDA
• State substitution rules for non-equivalent dosage forms

For a conventional tablet or injection, litigation exposure is likely lower than in markets with active formulation patents. For a new oral solution or orally disintegrating tablet, the sponsor could create its own patent estate and become the reference product for later ANDA entrants.

Which companies compete in the benztropine market?

Competition includes generic manufacturers, contract manufacturers, hospital suppliers, and distributors. The precise supplier mix varies by strength, dosage form, wholesaler inventory, and product discontinuations.

Competitive advantages are likely to come from:

• Reliable supply of all three tablet strengths
• Consistent availability of the injectable product
• Low minimum order quantities
• Unit-dose and blister packaging
• Long-dated inventory
• Institutional contracting
• Simple conversion from existing tablet products
• Controlled excipient sourcing

Because benztropine is inexpensive, a premium product must demonstrate a measurable operational benefit. A hospital may value a preservative-free single-dose injection or ready-to-administer package more than a modest tablet redesign.

What manufacturing and excipient barriers affect commercial entry?

The molecule does not present the same high barrier as a complex biologic, but manufacturing controls remain important.

Oral manufacturing barriers

The main challenges are:

• Low-dose blending and segregation
• Uniformity at the 0.5 mg strength
• Lubricant sensitivity
• Tablet friability
• Dissolution reproducibility
• Moisture control
• Color and strength differentiation

A co-processed excipient platform can reduce development time if it improves flow and compressibility without creating unusual dissolution behavior.

Injectable manufacturing barriers

Injectable entry requires:

• Sterile manufacturing capacity
• Validated aseptic processing
• Container closure integrity
• Particulate and endotoxin control
• Stability under storage and shipping conditions
• Compatibility with syringes, vials, and infusion components

A ready-to-use syringe could improve workflow but would increase device, fill-finish, and extractables-and-leachables requirements.

How strong is the patent estate for a new Cogentin formulation?

The patent estate for the old immediate-release product is weak as a source of market exclusivity because the active ingredient and conventional dosage forms are established. The estate for a new formulation could be moderate if it combines several defensible features:

• A specific excipient ratio
• A defined dissolution profile
• Improved stability
• A novel taste-masking system
• A preservative-free injectable composition
• A specialized container closure
• A clinically supported dosing advantage

A broad claim covering “benztropine with pharmaceutically acceptable excipients” would be vulnerable. Stronger claims would link composition to measurable performance, such as stability, dissolution, reduced degradation, improved bioavailability, or administration convenience.

What revenue exposure and commercial opportunities exist?

Public companies generally do not report Cogentin revenue separately, so product-level revenue exposure cannot be quantified from public filings. The market is likely small relative to major CNS products and is exposed to generic price erosion.

The most credible opportunities are:

1. Institutional injection supply, where shortages and vendor reliability affect purchasing.
2. Oral solution or orally disintegrating tablets for dysphagia and dose titration.
3. Unit-dose packaging for hospitals and long-term-care pharmacies.
4. Multi-strength portfolios that reduce pharmacy substitution complexity.
5. Contract manufacturing and private-label supply.
6. Excipient platform licensing for low-dose uniformity and taste masking.

A launch based solely on another conventional tablet is unlikely to support substantial pricing power. A product with a distinct dosage form, clear administration benefit, or more reliable injectable supply has a stronger commercial case.

Key Takeaways

• Cogentin is benztropine mesylate, an established small-molecule anticholinergic.
• The core tablet and injectable products are generic-market opportunities with limited apparent current exclusivity.
• Conventional excipients include lactose, starch, talc, magnesium stearate, aqueous vehicles, and tonicity agents, depending on the product.
• The strongest formulation opportunities are orally disintegrating tablets, oral solution, preservative-free injection, and unit-dose packaging.
• Low-dose content uniformity is a central technical issue for the 0.5 mg tablet.
• A standard generic tablet is likely to face intense price competition.
• New formulations would likely require a 505(b)(2) strategy and could support new patents and regulatory exclusivity.
• Biosimilar competition is irrelevant because benztropine is a small molecule.
• Commercial value is more likely to come from supply reliability, institutional packaging, and administration advantages than from active-ingredient patents.
• Current Orange Book and FDA product listings should govern product-specific filing and launch decisions.[3,4]

FAQs

Can a benztropine oral solution receive patent protection?

Yes. Protection could cover a specific solubilization system, preservative combination, pH range, stability profile, taste-masking system, or container. The claims must be tied to a novel and non-obvious formulation.

Is benztropine suitable for an orally disintegrating tablet?

Yes, from a formulation perspective. The main development issues are taste, dose uniformity, moisture sensitivity, tablet strength, and packaging. The regulatory pathway would depend on the reference product and the extent of formulation change.

Does benztropine have biosimilar risk?

No. Benztropine is a chemically synthesized small molecule. Competition comes from generic drugs, not biosimilars.

Would a preservative-free benztropine injection command a premium?

It could in hospital and emergency-care channels if it reduces preservative exposure, simplifies single-dose administration, or improves medication-use compliance. The premium would need to offset higher sterile fill-finish and packaging costs.

Can excipients improve benztropine tolerability?

Excipients can improve administration, taste, dissolution, or dose consistency, but they do not remove the pharmacologic anticholinergic adverse effects associated with benztropine. A tolerability claim would require clinical evidence and could not be inferred from excipient selection alone.

References

1. DailyMed. (n.d.). Cogentin and benztropine mesylate prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/